Cetrorelix acetate | CAS:120287-85-6

We serve Cetrorelix acetate CAS:120287-85-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Cetrorelix acetate

Chemical Name:Cetrorelix acetate
CAS.NO:120287-85-6
Synonyms:Cetrorelix acetate
cetrorelix
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Molecular Formula C70H92ClN17O14
Molecular Weight 1431.038
Index of Refraction 1.668
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Cetrorelix acetate is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders.



Contact us for information like Cetrorelix acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,cetrorelix physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Cetrorelix acetate Use and application,Cetrorelix acetate technical grade,usp/ep/jp grade.


Related News: The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.5-Bromo-2-methoxy-3-nitropyridine manufacturer The risk to the general public remains low. And we continue to be confident we are in a good position to respond to this developing situation.”(alphaR)-alpha-[[[2-(4-Aminophenyl)ethyl]amino]methyl]benzenemethanol hydrochloride supplier The risk to the general public remains low. And we continue to be confident we are in a good position to respond to this developing situation.”3-(1-ethoxyethoxy)-4-phenylazetidin-2-one vendor An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.